Skip to content

The effect of remimazolam on diaphragm function in patients undergoing gynecological hysteroscopic surgery.

The effect of remimazolam on diaphragm function in patients undergoing gynecological hysteroscopic surgery.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102592
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-05-20
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic diseases of the uterus

Interventions

remimazolam group:The experimental group was treated with remimazolam combined with low-dose propofol
Propofol group:The control group was treated with propofol

Sponsors

Xi'an People's Hospital (Xi'an No.4 Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II 2. Patient age: 18 - 65 years old, voluntarily requesting hysteroscopic surgery; 3. Patients have no allergic reactions to the anesthetic drugs involved in this study and no history of other drug allergies; 4. Patients are conscious, have normal responses and good communication skills; 5. All have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular diseases, including unstable angina pectoris that is not well controlled, hypertension, etc.; 2. Severe liver and kidney dysfunction; 3. Patients in the acute stage of asthma attack, with acute respiratory tract infection or with a high suspicion of difficult airway; 4. Patients with severe mental disorders or those who have been taking psychotropic drugs for a long time; 5. Patients with respiratory muscle paralysis or deformities such as scoliosis that seriously affect their respiratory function; 6. Patients with a significant history of major thoracic and abdominal surgeries.

Design outcomes

Primary

MeasureTime frame
Diaphragmatic mobility ;diaphragm thickening fractions;

Secondary

MeasureTime frame
Hemodynamic monitoring;Respiratory monitoring;

Countries

China

Contacts

Public ContactLiu Qian

Xi'an People's Hospital (Xi'an No.4 Hospital)

312353652@qq.com+86 155 9219 8125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026